Supplementation with urocortin markedly reduced the levels of TGF-β1 and CTGF as compared with DM treatment (P<0.01), while supplementation with urocortin and triciribine partially reduced the TGF-β1 and CTGF levels when compared with urocortin treatment alone (P<0.05). This evidence concerns the gene CCN2 and diabetes mellitus.